The median overall survival of FLT3mut AML was shorter at 12.5 months compared to 14.7 months for wild-type FLT3 [43], suggesting some degree of FLT3-mediated venetoclax resistance. The gene discussed is FLT3; the disease is acute myeloid leukemia.